Portal de Periódicos da CAPES

Measurements of Plasma Endothelin Immunoreactivity in Healthy Cats and Cats with Cardiomyopathy

2004; Wiley; Volume: 18; Issue: 6 Linguagem: Inglês

10.1892/0891-6640(2004)18 2.0.co;2

1939-1676

Robert A. Prosek, D. David Sisson, Mark A. Oyama, Alexander Welker Biondo, Philip F. Solter,

Nitric Oxide and Endothelin Effects

Journal of Veterinary Internal MedicineVolume 18, Issue 6 p. 826-830 Open Access Measurements of Plasma Endothelin Immunoreactivity in Healthy Cats and Cats with Cardiomyopathy Robert Prošek, Corresponding Author Robert Prošek Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL. The Heart Center for Animals at Miami Veterinary Specialists, Coral Gables, FL and The Heart Center for Animals, Homestead, FL. Veterinary Specialists, Inc., 91 NE 6th Street, Homestead, FL 33030; e-mail: [email protected].Search for more papers by this authorD. David Sisson, D. David Sisson Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL.Search for more papers by this authorMark A. Oyama, Mark A. Oyama Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL.Search for more papers by this authorAIexander W. Biondo, AIexander W. Biondo Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL. Departamento de Medicina Veterinaria, Universidade Federal do Parana, Curitiba—Parana, Brazil.Search for more papers by this authorPhilip F. Solter, Philip F. Solter Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL.Search for more papers by this author Robert Prošek, Corresponding Author Robert Prošek Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL. The Heart Center for Animals at Miami Veterinary Specialists, Coral Gables, FL and The Heart Center for Animals, Homestead, FL. Veterinary Specialists, Inc., 91 NE 6th Street, Homestead, FL 33030; e-mail: [email protected].Search for more papers by this authorD. David Sisson, D. David Sisson Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL.Search for more papers by this authorMark A. Oyama, Mark A. Oyama Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois, Urbana, IL.Search for more papers by this authorAIexander W. Biondo, AIexander W. Biondo Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL. Departamento de Medicina Veterinaria, Universidade Federal do Parana, Curitiba—Parana, Brazil.Search for more papers by this authorPhilip F. Solter, Philip F. Solter Department of Veterinary Pathobiology, College of Veterinary Medicine, University of Illinois, Urbana, IL.Search for more papers by this author First published: 05 February 2008 https://doi.org/10.1111/j.1939-1676.2004.tb02628.xCitations: 21 Preliminary results were presented at the ACVIM 21st Annual Forum, Charlotte, NC, June 2003. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Plasma concentrations of endothelin-1 (ET-1), the most potent endogenous pressor substance discovered to date, are abnormally high in humans with congestive heart failure (CHF), and they correlate with the degree of functional impairment. We sought first to validate a human sandwich ELISA kit that targets that portion of the amino acid sequence that is identical in cats. The assay demonstrated linearity (R2= .9968) and parallelism (P= .5339), recovery of spiked human ET-1 in cat plasma averaged 98.7%, and intraassay precision had a coefficient of variation <10%. We subsequently determined ET-1 immunoreactivity in healthy cats and in cats with myocardial disease with and without CHF, systemic thromboembolism (STE), or both. Plasma ET-1 immunoreactivity was measured in 12 healthy cats and in 28 cats with primary myocardial disease, including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), or restrictive or unclassified cardiomyopathy (RCM and UCM), respectively. Plasma ET mean (95% CI) concentrations were 0.777 (0.6536-0.924) fmol/mL in the control cats, 1.427 (0.922-2.209) fmol/mL in 12 cats with cardiomyopathy (HCM = 11, RCM/UCM = 1) but without CHF or evidence of STE, and 2.360 (1.666-3.343) fmol/mL in 16 cats with cardiomyopathy (HCM = 8, RCM/UCM = 7, DCM = 1) and CHF (n = 15) or STE (n = 4). Plasma immunoreactivity of ET-1 was significantly higher in cats with myocardial disease without CHF/STE versus normal cats (P <.05) and in cats with myocardial disease with CHF/STE versus normal cats (P <.001). References 1 Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415. 2 Inoue A., Yanagisawa M., Kimura S., et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989; 26: 2863–2867. 3 Gray GA. Generation of endothelin. In: GA Gray, DJ Webb, eds. Molecular Biology and Pharmacology of Endothelins. Austin : RG Landes; 1995: 13–32. 4 Biondo AW, Wiedmeyer CE, Sisson DD, Solter PF. Comparative sequences of canine and feline endothelin-1. Vet Clin Pathol 2003; 32: 188–194. 5 McMurray JJ, Ray SG, Abdullah I., Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 1992; 85: 1374–1379. 6 Pacher R., Bergler-Klein J., Globis S., et al. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993; 71: 1293–1299. 7 Shubeita HE, McDonough PM, Harris AN, et al. Endothelin induction of inositol phospholipids hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: a paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990; 265: 20555–20562. 8 Guarda E., Katwa LC, Myers PR, et al. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993; 27: 2130–2134. 9 Bogoyevitch MA, Glennon PE, Anderson MB, et al. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J Biol Chem 1994; 269: 1110–1119. 10 Knuepfer MM, Han SP, Trani AJ, et al. Regional hemodynamic and baroreflexes effects of endothelin in rats. Am J Physiol 1989; 257: H918–H926. 11 van den Buuse M., Itoh S. Central effects of endothelin on baro-reflex of spontaneously hypertensive rats. J Hypertension 1993; 11: 379–387. 12 Kannan H., Tanaka H., Ueta Y., et al. Effects of centrally administered endothelin-3 on renal sympathetic nerve activity and renal blood flow in conscious rats. J Auton Nerv Syst 1994; 49: 105–113. 13 Fox PR. Feline cardiomyopathies. In: PR Fox, DD Sisson, NS Moise, eds. Textbook of Canine and Feline Cardiology. Philadelphia : WB Saunders; 1999: 621–678. 14 Sahn DJ, DeMaria A., Kisslo J., Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–1083. 15 Zar JH. Biostatistical Analysis, 4th ed. Englewood Cliffs , NJ : Prentice Hall; 1998. 16 Goto K., Hama H., Kasuya Y. Molecular pharmacology and pathophysiologic significance of endothelin. Jpn J Pharmacol 1996; 72: 261–290. 17 Battistini B., Forget MA, Laight D. Potential roles for endothelins in systemic inflammatory response syndrome with a particular relationship to cytokines. Shock 1996; 5: 167–183. 18 Jougasaki M., Larsen AM, Cataliotti A., Christiansen DC, Burnett JC Jr. Cardiotrophin-1 stimulates endothelin-1 via gp130 in vascular endothelial cells. Peptides 2002; 23: 1441–1447. 19 Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989; 86: 2863–2867. 20 Hahn AW, Resink TJ, Scott-Burden T., Powell J., Dohi Y., Buhler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul 1990; 1: 649–659. 21 Komuro I., Kurihara H., Sugiyama T., et al. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett 1988; 238: 249–252. 22 Sugden PH, Fuller SJ, Mynett JR, et al. Stimulation of adult rat ventricular myocyte protein synthesis and phosphoinositide hydrolysis by the endothelins. Biochem Biophys Acta 1993; 1175: 327–332. 23 Suzuki T., Hoshi H., Mitsui Y. Endothelin stimulates hypertrophy and contractility of neonatal rat cardiac myocytes in a serum-free medium. FEBS Lett 1990; 268: 149–151. 24 Morbidelli L., Orlando C., Maggi CA, Ledda F., Ziche M. Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol 1995; 269: H686–H695. 25 Levin ER. Endothelins as cardiovascular peptides. Am J Nephrol 1996; 16: 246–251. 26 Levin ER. Endothelins. N Engl J Med 1995; 333: 356–363. 27 Davenport AP, Ashby MJ, Easton P., et al. A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: comparison concentrations in patients with essential hypertension and normotensive control subjects. Clin Sci (Lond) 1990; 78: 261–264. 28 Kohno M., Yanasuri K., Murakawa K., et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88: 614–618. 29 Wei CM, Lerman A., Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580–1586. 30 Kiowski W., Sutsch G., Hunziker P., et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995; 346: 732–736. 31 Sutsch G., Bertel O., Kiowski W. Acute and short-term effects of the nonpeptide endothelin-1 receptor antagonist bosentan in humans. Cardiovasc Drugs Ther 1997; 10: 717–725. 32 Rossi GP, Cavallin M., Nussdorfer GG, Pessina AC. The endothelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol 2001; 38(Suppl 2): S49–S52. 33 Hasegawa K., Fujiwara H., Koshiji M., et al. Endothelin-1 and its receptor in hypertrophic cardiomyopathy. Hypertension 1996; 27: 259–264. 34 Ficai S., Herizi A., Mimran A., Jover B. Endothelin blockade in angiotensin II hypertension: prevention and treatment studies in the rat. Clin Exp Pharmacol Physiol 2001; 28: 1100–1103. 35 Bauer M., Wilkens H., Langer F., et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002; 105: 1034–1036. 36 Ivy DD, Yanagisawa M., Gariepy CE, et al. Exaggerated hypoxic pulmonary hypertension in endothelin B receptor-deficient rats. Am J Physiol Lung Cell Mol Physiol 2002; 282: L703–L712. 37 Lee JH, Chun YG, Lee IC, et al. Pathogenic role of endothelin 1 in hemodynamic dysfunction in experimental acute pulmonary thromboembolism. Am J Respir Crit Care Med 2001; 164: 1282–1287. 38 Ohnishi M., Wada A., Tsutamoto T., et al. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure. Clin Sci (Lond) 2002; 103(Suppl 48): 241S–244S. 39 Sakai S., Miyauchi T., Kobayashi M., et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384: 353–355. 40 Shimoyama H., Sabbah HN, Borzak S., et al. Short-term hemodynamic effects of endothelin receptor blockade in dogs with chronic heart failure. Circulation 1996; 94: 779–784. 41 Mishima T., Tanimura M., Suzuki G., et al. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol 2000; 35: 222–229. 42 Sakai S., Miyauchi T., Kobayashi M., et al. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384: 353–355. Citing Literature Volume18, Issue6November 2004Pages 826-830 ReferencesRelatedInformation